Open Label, Dose Escalation Trial of Oral 4SC-205 in Patients With Advanced Malignancies: First-In-Man Study of a Newly Developed, Oral Inhibitor of Kinesin-spindle Protein, Eg5

Trial Profile

Open Label, Dose Escalation Trial of Oral 4SC-205 in Patients With Advanced Malignancies: First-In-Man Study of a Newly Developed, Oral Inhibitor of Kinesin-spindle Protein, Eg5

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs 4SC 205 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms AEGIS
  • Sponsors 4SC
  • Most Recent Events

    • 03 Jun 2015 According to 4 SC Media Release, clinical data from this trial was published at the annual meeting of the American Society of Clinical Oncology (ASCO).
    • 03 Jun 2015 Results published in the 4 SC Media Release.
    • 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top